NCI-2018-00438, NCT03552471: Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer |
|
|
| Active, not recruiting | 1 | 25 | US | Laboratory Biomarker Analysis, Mirvetuximab Soravtansine, IMGN853, M9346A-sulfo-SPDB-DM4, Pharmacokinetic Study, PHARMACOKINETIC, PK Study, Rucaparib Camsylate, 8-Fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one ((1S,4R)-7,7dimethyl-2-oxobicyclo[2.2.1]hept-1-yl)methanesulfonic Acid Salt, C0-338, Rubraca, Rucaparib Phosphate | Ohio State University Comprehensive Cancer Center, ImmunoGen, Inc., Clovis Oncology, Inc. | BRCA1 Gene Mutation, BRCA2 Gene Mutation, Folate Receptor Alpha Positive, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Recurrent Uterine Corpus Carcinoma, Recurrent Uterine Serous Carcinoma, Recurrent Uterine Carcinosarcoma, Platinum Resistant Ovarian Cancer | 06/22 | 12/23 | | |
NCT05483933: Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian Cancers |
|
|
| Active, not recruiting | 1 | 86 | Europe, Canada, US | Pegylated Liposomal Doxorubicin + SL-172154, Doxil, PLD, Caelyx, Mirvetuximab + SL-172154, IMGN853, MIRV | Shattuck Labs, Inc. | Platinum-resistant Ovarian Cancer, Fallopian Tube Cancer, Epithelial Ovarian Cancer, Ovarian Cancer, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Primary Peritoneal Carcinoma | 07/24 | 04/25 | | |
